RE: France11 Mar 2021 18:13
Henner,
I hope you don't mind me jumping in. I've just signed up and googled translated.
Amiens University Hospital: a treatment trial against Covid-19 labeled "national priority" for research
Treatment involves offering interferon-beta through the lungs to patients on oxygen therapy. About twenty patients have already received it.
Photo caption:
Treatment involves offering interferon-beta through the lungs - where the virus is most prevalent - by breathing it in through a mask, for a minimum of eight days. (Archive photo)
Treatment involves offering interferon-beta through the lungs - where the virus is most prevalent - by breathing it in through a mask, for a minimum of eight days. (Archive photo)
Intro
The Amiens University Hospital took care of the first patient with the coronavirus a year ago. Will it now make it possible to validate a first effective treatment against covid-19? A project promoted by the reference hospital in Picardy for several months is shaping up to be very promising in any case. So much so that this test, dubbed “COV-NI”, received the “national research priority” label at the end of January by an ad hoc committee (CAPNET) set up by the government. While since March 2020, around 100 clinical trials on possible treatments for the disease have been authorized, only 22 studies have been selected.
Treatment involves offering interferon-beta through the lungs - where the virus is most prevalent - by breathing it in through a mask, for a minimum of eight days. Interferons are not complete strangers. These antiviral defense cytokines, natural proteins, are already used in particular for the treatment of multiple sclerosis in the subcutaneous route. Original, "the inhaled form presents less iatrogenic risk (harmful) and makes it possible to achieve more effective local concentrations than with parenteral forms (by injection under the skin)", describes the presentation of the research project.
146 patients across the region
Initially planned to cover 60 patients, the "multicentric" trial will ultimately include 146 patients treated under oxygen therapy, "sufficiently early in the illness", hospitalized in Amiens, Saint-Quentin, Abbeville, Compiègne, Valenciennes and Bethune. Already, "20 patients have been able to receive the product," says Dr. Aurélien Mary, doctor of science and pharmacy and clinical pharmacist in the intensive care unit at the University Hospital of Amiens, at the origin of this sustained study. by several other caregivers and researchers from the CHU, including Doctor Jean Philippe Lanoix, principal investigator of the study, and Professor Michel Brazier, pharmacist and biologist. Four other patients with advanced disease were also treated "on a compassionate basis" with nebulized Interferon (IFN). "They all survived."
Sign In
Follow the stocks
